子宫腺肌病对体外受精的影响:长效与超长效促性腺激素释放激素激动剂治疗后的比较
本研究为观察性队列研究,纳入了卵巢储备正常、首次接受体外受精治疗的三组患者:A组362例子宫腺肌病患者采用超长效促性腺激素释放激素激动剂方案,B组127例子宫腺肌病患者采用长效促性腺激素释放激素激动剂方案,C组3471例输卵管性不孕患者采用长效促性腺激素释放激素激动剂方案。结果显示,在长效促性腺激素释放激素激动剂方案下,子宫腺肌病患者的临床妊娠率、着床率和活产率均低于输卵管性不孕患者,流产率升高;而对于子宫腺肌病患者,超长效方案相比长效方案的临床妊娠率、着床率和活产率均有所提高。
要点
- 在长效促性腺激素释放激素激动剂方案下,子宫腺肌病患者的临床妊娠率、着床率和活产率均低于输卵管性不孕患者
- 子宫腺肌病患者采用超长效促性腺激素释放激素激动剂方案者的临床妊娠率、着床率和活产率均高于采用长效方案者
- 超长效促性腺激素释放激素激动剂方案组的获卵数减少,促性腺激素用量和持续时间增加
核心结论
- 在长效促性腺激素释放激素激动剂方案下,子宫腺肌病可独立于卵巢储备对体外受精结局产生负面影响
- 子宫腺肌病患者采用超长效促性腺激素释放激素激动剂方案可能获得比长效方案更好的妊娠结局
研究设计与样本
- 观察性队列研究,纳入卵巢储备正常、首次接受体外受精治疗的三组患者
- A组:362例子宫腺肌病患者,采用超长效促性腺激素释放激素激动剂方案
- B组:127例子宫腺肌病患者,采用长效促性腺激素释放激素激动剂方案
- C组:3471例输卵管性不孕患者,采用长效促性腺激素释放激素激动剂方案
主要发现
- 与B组和C组相比,A组获卵数减少,促性腺激素用量和持续时间增加(P < 0.001)
- 在长效促性腺激素释放激素激动剂治疗中,子宫腺肌病患者相比输卵管性不孕患者,临床妊娠率降低(OR 0.492,95% CI 0.327至0.742,P < 0.001),着床率降低(OR 0.527,95% CI 0.350至0.794,P = 0.002),活产率降低(OR 0.442,95% CI 0.291至0.673,P < 0.001),流产率升高(OR 3.078,95% CI 1.593至5.948,P < 0.001)
- 对于子宫腺肌病患者,超长效促性腺激素释放激素激动剂治疗相比长效治疗,临床妊娠率升高(OR 1.925,95% CI 1.137至3.250,P = 0.015),着床率升高(OR 1.694,95% CI 1.006至2.854,P = 0.047),活产率升高(OR 1.704,95% CI 1.012至2.859,P = 0.044)
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Does adenomyosis affect IVF independent of decreased ovarian reserve, and what are the characteristics and IVF outcome of the ultra-long gonadotrophin-releasing hormone (GnRH) agonist protocol in adenomyosis? DESIGN: Observational cohort study of three groups of patients undergoing first cycle of IVF treatment with normal ovarian reserve: (A) 362 patients with adenomyosis using the ultra-long GnRH agonist protocol; (B) 127 patients with adenomyosis using the long GnRH agonist protocol; (C) 3471 patients with tubal infertility using the long GnRH agonist protocol. RESULTS: Compared with groups B and C, the number of oocytes retrieved in group A decreased, and the gonadotrophin dosage and duration in group A were higher (P < 0.001). In long GnRH agonist treatment, clinical pregnancy rate (OR 0.492, 95% CI 0.327 to 0.742, P < 0.001), implantation rate (OR 0.527, 95% CI 0.350 to 0.794, P = 0.002) and live birth rate (OR 0.442, 95% CI 0.291 to 0.673, P < 0.001) decreased and miscarriage rate (OR 3.078, 95% CI 1.593 to 5.948, P < 0.001) increased in adenomyosis patients compared with tubal infertility. For adenomyosis patients, clinical pregnancy rate (OR 1.925, 95% CI 1.137 to 3.250, P = 0.015), implantation rate (OR 1.694, 95% CI 1.006 to 2.854, P = 0.047) and live birth rate (OR 1.704, 95% CI 1.012 to 2.859, P = 0.044) increased in the ultra-long GnRH agonist treatment compared with long GnRH agonist treatments. CONCLUSION: Adenomyosis could negatively affect IVF outcomes independent of ovarian reserve after long GnRH agonist protocol. Patients with adenomyosis following the ultra-long GnRH agonist protocol could have a better pregnancy outcome than those following the long GnRH agonist protocol.
引用
- Hou X, Xing J, Shan H, et al. The effect of adenomyosis on IVF after long or ultra-long GnRH agonist treatment. Reprod Biomed Online. 2020. PMID: 32972873. doi:10.1016/j.rbmo.2020.07.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。